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ABSTRACT 
Objective: We investigated the separate effects of and possible interactions between the functional 
polymorphisms of brain-derived neurotrophic factor (BDNF) rs11030101, BDNF rs61888800, and 
neuregulin-1 (NRG1) rs3924999 and NRG1 rs6994992 on change of temperament scores in a clinical sample 
of subjects with major depression (MDD), who received selective serotonin reuptake inhibitor (SSRI) 
treatment for a period of six weeks.  
 
Methods: The study population consisted of 98 Finnish individuals with MDD. They were assessed by the 
107-item Temperament and Character Inventory (TCI) temperament questionnaire (version IX) and the 
Montgomery-Åsberg Depression Rating Scale (MADRS). In general linear univariate models (GLM) for 
Novelty Seeking (NS) or Reward Dependence (RD) change age, gender, MADRS score change and BDNF and 
NRG1 genotypes were used as explaining explanatory variables.   
 
Results: Mean comparisons between corresponding temperament dimensions and genotypes showed 
significant differences between NS change and BDNF rs61888800 T-carrying status (mean difference: GG 
0.30, GT/TT 2.47, p=0.022, T-test) and between RD change and NRG1 rs3924999 A-carrying status (mean 
difference: GG 1.21, GA/AA -0.33, p=0.003). In GLM models for NS change the significant predictors 
comprised BDNF rs61888800 T-carrying status, age and MADRS score change (model 1), and additionally 
NRG1 rs6994992 T-carrying status (model 2). For RD change the predictors included NRG1 rs3924999 A-
carrying status, age and MADRS score change (model 1) and additionally gender (model 2). 
 
Conclusion: According to the current results both BDNF and NRG1 are associated with temperament traits 
during depression. These results warrant further studies regarding the impact of this association on 
depression recovery.  
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SIGNIFICANT OUTCOMES 
The T-carriers of BDNF rs61888800 had a more favourable temperament change on the NS dimension 
towards recovery than did the GG-carriers. For NRG1 rs3924999, the GG genotype showed a more 
favourable change in RD than the A-carriers. 
 
LIMITATIONS 
Small study sample, lack of replication sample, relatively short follow-up time and single-nucleotide 
polymorphism (SNP) analyses are the limitations of the present study.  
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INTRODUCTION 
 
The diagnosis of major depression (MDD) has been defined as a cluster of specific symptoms, including 
among others depressed mood, anhedonia and lack of energy, but the clinical features of an individual 
patient are heterogeneous and therefore prediction of treatment response is challenging. There is a need 
for biological markers as outcome measures, because currently used depression measures are based on 
reporting of clinical symptoms, while each measure has its limitations and therefore measuring outcome 
lacks accuracy. 
 
Temperament patterns can be observed since early infancy and have been associated with thickness of 
cortex in infants (1).  Brain-derived neurotrophic factor (BDNF) is a protein involved in the proliferation, 
differentiation and survival of neuronal cells and in the regulation of synaptic plasticity and connectivity in 
the adult brain, and BDNF has been associated with personality traits, temperament and depression (2, 3). 
BDNF also has a possible role in regulating interactions between neurons and microglia (4). Neuregulin-1 
(NRG1) is a neurotrophic factor that has been associated with treatment response to serotonin selective 
antidepressive agents in MDD and with the risk of major depression (5, 6).  NRG1 has been found to induce 
activation in tropomyosin-related kinase B (TrkB), which is a receptor of BDNF, and the receptor has been 
found to mediate neural plasticity and is also reportedly involved in the mechanisms of action of 
antidepressive drugs (7). Both NRG1 and BDNF induce myelination in the central nervous system by 
oligodendrocytes through increasing N-methyl-D-aspartate (NMDA) receptor currents (8). We wanted to 
investigate the association between both neurotrophic factors BDNF and NRG1 and temperament in 
presence of major depressive disorder.  
 
Temperament has in general been defined as the innate part of the human personality as opposed to 
learned features (9). Cloninger developed a psychobiological personality model describing four dimensions 
of temperament, namely Harm Avoidance (HA), Novelty Seeking (NS), Reward Dependence (RD) and 
Persistence (P). The temperament dimensions in Cloninger’s model are suggested to present different 
dimensions of automatic neural responses possibly associated with specific monoaminergic activity (10).  
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According to a meta-analysis patients with major depressive disorder have been shown to have higher 
score in Harm Avoidance and lower scorers in the other three temperament dimensions (11). More 
specifically, the Harm Avoidance score level has showed to be inversely associated with euthymia in 
depressive disorder (11). The relationship between temperament and depression has been supported in a 
number of studies as an association with the risk of depression, risk of recurrence and impact on treatment 
response (11-20). According to many studies the temperamental changes during recovery from depression 
include a marked decrease in HA and to some extent an increase in RD (21).  
 
Since the temperamental traits during depressive state can be regarded as a result of abnormal neuronal 
processing, this abnormality could be a consequence of a genetic vulnerability in the genes involved in 
neural regeneration mechanisms. Several single-nucleotide polymorphisms (SNPs) in BDNF gene have been 
associated with antidepressant response (22).  The BDNF gene has been suggested to have an important 
role in the pathogenesis of depression, and moreover in neurogenesis and synaptogenesis during 
antidepressant drug treatment (7,23). The rs11030103 has been associated with major depression (22), but 
in other studies no association was found (24,25). In another study rs11030103 of BDNF, but not 
rs61888800, was found to be associated with a change in MADRS score among patients receiving 
electroconvulsive therapy (ECT) (26).  The rs11030101 of BDNF has been reported to be associated with 
depression and the rs61888800 of BDNF with better response to antidepressant treatment (22), although 
other studies did not support this finding (24, 27). NRG1 has been found to have an important function in 
neurodevelopment, neurotransmission and synaptic plasticity (28).  In a large case-control study, rs 
3924999 and several other NRG1 SNPs and haplotypes have been associated with the risk of major 
depression, bipolar disorder and schizophrenia (6). The rs6994992 of NRG1 has been associated to 
depression symptom severity, psychotic symptom patterns and alcohol use disorders (29,30).  
 
Studies exploring associations between temperament and genetic variations in BDNF or NRG1 in major 
depression are so far rare. Mandelli et al.  in a sample of 86 bipolar spectrum depressed patients reported 
both BDNF haplotype of SNPS rs6265 and rs11030104 (A-C) and higher HA score to be associated with 
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poorer six-month treatment response, but HA scores were not associated with these BDNF genotypes (31). 
In a meta-analysis NRG1 was found to potentially affect selective serotonin reuptake inhibitor (SSRI) 
treatment and NRG1 has been suggested to be a biomarker for depression (5).  
 
We investigated the separate effects of and possible interactions between functional polymorphisms BDNF 
rs11030101, BDNF rs61888800, NRG1 rs3924999 and NRG1 rs6994992 polymorphisms on changes in 
temperament dimension scores (HA, NS, RD, P) assessed by the Temperament and Character Inventory 
(TCI) in a clinical sample of subjects with major depression, who received SSRI-treatment for a period of six 
weeks. 
 
METHODS 
Study subjects and clinical intervention 
 
The study population consisted of 98 Finnish individuals 19-72 years of age (41 males and 57 females, 
mean age [SD] 40.5 [14.1] years). All subjects were patients in secondary outpatient services in Pirkanmaa 
Hospital District, Finland (total catchment population approximately 300,000). The inclusion criteria were: 
1) current episode of major depressive disorder according to Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) criteria and 2) a Montgomery-Åsberg Depression Rating Scale (MADRS) (32) 
score of at least 20. The doses of the study medication were adjusted according to the clinical response, 
which was checked during a visit after three weeks of treatment. Medication adherence was self-
monitored by keeping a paper-and-pencil medication diary. We considered an adherence rate of at least 80 
% as adequate treatment. Each patient was interviewed by clinical researchers, who were all experienced 
psychiatrists before the initial assessment for the study. In the initial assessment the DSM checklist for the 
MDD was fulfilled for each patient. Major somatic diseases, with medications potentially causing 
depression, bipolar disorder, schizophrenia, severe personality disorders or disorders related to substance 
abuse were considered as exclusion criterion. Patients treated for previous depressive episodes had to be 
free from antidepressants for the past three months, and mood stabilizing or antipsychotic medications 
were not allowed. Anxiolytics and hypnotics in minor doses were permitted at the early stage of the study. 
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Most of the patients (n=80, 81%) had no history of previous depressive episodes vs patients with previous 
depressive episodes (n=18, 18.4%). 
 
The Temperament and Character Inventory (TCI) is a questionnaire developed to distinguish the four 
dimensions (9). For assessment of temperament dimensions all study subjects completed the 107-item TCI 
temperament questionnaire (version IX) in the presence of clinical researcher and MADRS interview was 
performed at the initial assessment of the study and after six weeks of follow-up. For six weeks the 
patients received SSRI medication, citalopram, fluoxetine or paroxetine (the three most frequently 
prescribed SSRIs in Finland at the time the study). Citalopram was used by 51 patients (52.0%), fluoxetine 
was by 35 patients (35.7%), and paroxetine by 12 patients (12.2%). Out of 57 females 26 (45.6%) were 
using citalopram, 22 (38.6%) fluoxetine and 9 paroxetine (15.8%). Out of all males 25 (61%) were using 
citalopram, 13 (31.7%) fluoxetine and 3 (7.3%) paroxetine. The treatment response was determined as at 
least 50% MADRS score reduction. All subjects gave written informed consent and the local ethics 
committee approved the study protocol. 
 
DNA extraction and BDNF rs11030101, BDNF rs61888800, NRG1 rs3924999 and NRG1 rs6994992 
genotyping 
Genomic DNA was extracted from peripheral blood leucocytes using the QIAamp DNA Blood Minikit and 
automated biorobot M48 extraction (Qiagen, Hilden, Germany). BDNF gene alterations rs11030101 and 
rs61888800 were genotyped using Taqman SNP Genotyping Assays C___1751785_10 and C__89097203_10 
respectively and the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, 
California, USA). Ten random samples were run as duplicates. No discrepancies were found. 
 
Statistical methods 
MADRS baseline and endpoint scores were compared between the studied genotypes by using ANOVA. For 
exploratory analysis, Pearson’s correlations between BDNF and NRG1 genotypes and scores for changes in 
temperament dimensions from baseline to six weeks were calculated to select the temperament 
dimensions for the general linear univariate model (GLM). T-test was used in the calculation of mean 
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differences between temperament score changes between the BDNF and NRG1 genotype groups. GLM 
models were used to predict NS and RD change. These models were adjusted for age, gender and MADRS 
score change, and BDNF and NRG1 genotypes were used as explanatory variables. 
 
RESULTS 
 
The genotype distributions of both BDNF and NRG1 SNPs according to temperament dimensions and 
MADRS scores at baseline and endpoint are presented in Table 1. At six weeks 88 patients completed the 
TCI questionnaire and 87 the MADRS interview. BDNF rs11030101 genotyping failed in one patient. There 
were no significant differences in MADRS baseline or endpoint scores between any of the study genotypes 
(ANOVA). MADRS baseline or endpoint scores did not show significant correlations with temperament 
change scores, except for ΔHA (r=0.36, p=0.001) at endpoint. 
 
The correlation between BDNF rs61888800 T-carrying status and change in NS scores from baseline to six 
weeks was significant (r=0.23, p=0.034). A negative significant correlation was found between NRG1 
rs3924999 A-carrier status and RD change (r=-0.29, p=0.005). 
 
Mean comparisons between corresponding temperament dimensions and genotypes revealed significant 
differences between NS change and BDNF rs61888800 T-carrying status (mean difference: GG 0.30, GT/TT 
2.47, p=0.022, T-test) and between RD change and NRG1 rs3924999 A-carrying status (mean difference: GG 
1.21, GA/AA -0.33, p=0.003), but not between baseline or six-week NS score and BDNF genotype, or RD 
baseline or six-week score and NRG1 genotype. 
 
In GLM for NS and RD change age, gender, MADRS score change and BDNF or NRG1 genotypes were used 
as explanatory variables. The best fitting models for NS change comprised BDNF rs61888800 T-carrying 
status, age and MADRS score change (model 1). This model explained 11.8% of the variance of the NS-
change (ηp2 = 0.118) and when NRG1 T-carrying status was added to the model (model 2), it explained 
15.1% of NS change (ηp2 = 0.151). For RD change the best fitting models included NRG1 rs3924999 A-
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carrying status, age and MADRS score change (model 1). This model explained 14.9% of the variance of RD-
change (ηp2 =0.149) and when gender was added to the model (model 2), it explained 16.9% (ηp2=0.169) of 
the RD change. The results of the GLM models are presented in Table 2. 
 
DISCUSSION 
 
In this study we explored changes in temperament dimension scores at the acute stage of depression 
during six-week treatment with SSRI. We also analysed the levels of depressive symptoms before and after 
acute phase treatment between the BDNF and NRG1 genotypes. We found the T-carriers of BDNF 
rs61888800 to show an increase in NS score. The outcome measured with MADRS score change also had an 
effect on this difference in the multivariate analysis. Additionally, patients with GG-genotype in NRG1 
rs3924999 showed an increase in RD score during treatment, but the A-carriers did not show a similar 
change. For this difference the outcome did not have any effect in the multivariate analysis. We neither 
found any genotype effects in baseline or endpoint depression severity.  
 
There are so far no studies on the relationship between NS change and BDNF genotypes. HA levels were 
not associated with the present BDNF or NRG1 genotypes. Earlier studies have reported somewhat 
contradictory results on the relationship between HA, BDNF genotypes or serum concentrates. Kim et al. 
found BDNF Val/Val genotype of Val66Met polymorphism to be associated with higher HA after negative 
life stressors in a community sample (33), whereas Minelli et al. found Met-carriers of BDNF Val66Met 
genotype to have higher BDNF serum levels (34). In a study on healthy Caucasian subjects the Met/Met 
genotype of BDNF Val66Met polymorphism was associated with higher scores on Harm Avoidance 
subscales HA1 (anticipatory worry) and HA2 (uncertainty) (35), and in another study on healthy subjects 
the same genotype was associated with low HA total scores (36). A meta-analysis including 607 patients 
showed no association between BDNF Val66Met and HA (37). 
 
For the RD it is noteworthy that the changes in RD during recovery from depression have been found to be 
small in magnitude. During major depression increase in RD scores has been reported (21), and in general 
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sample studies there are findings of low RD being associated with risk of depression (10,38), and also with 
risk of suicide attempts (18). It is possible that the negative findings related to depression state-
dependency of RD are associated with 1) the small magnitude of the change and 2) different onset time of 
change in different patients. According to the present finding the patients with NRG1 rs3924999 GG-
genotype could represent a subpopulation with a relatively rapid recovery from the depressive state 
dependent changes in RD and the A-allele carriers may refer to prolonged trait-related changes. Verifying 
this hypothesis requires replication of the analysis in a larger sample and with a longer follow-up. The 
subscales RD2-RD4 are all related to social sensitivity, and the low RD score in depression could reflect the 
anhedonic state and result in impaired ability in social functioning. In animal models NRG1 has been 
reported to be associated with amygdala activation (39).  
 
BDNF and NRG1 genotypes may be associated with alterations in the brain neurotransmission system 
during recovery from depression.  The increase in NS scores among the T-carriers of BDNF rs61888800 
during the six weeks of treatment with SSRIs can be viewed as an expected change, because NS scores 
usually decrease during depressive state.  Among GG genotype of BDNF rs61888800 there seems to be a 
delay in recovery from depressive trait as measured by NS. However, over six weeks there were no 
differences in absolute response between these genotypes.  
 
 There is evidence from earlier research of lower NS and RD scores during depressive state (11) and of an 
increase of NS scores during recovery (40). According to the present results we could assume that the T-
carriers of BDNF rs61888800 undergo a more favourable temperament change towards recovery when 
compared to GG-carriers, who showed no change in NS scores. For NRG1 rs3924999, GG genotype had a 
more favourable change to RD than the A-carriers. The same result was obtained for both BDNF and NRG1 
genotypes using multivariate analysis considering confounding factors age and gender and treatment 
response in the model. Age and gender did not have any effect on the results of the multivariate analysis. 
According to Cloninger, temperament dimensions tend to be relatively stable throughout the life span, 
although some studies, e.g. Brändström et al., have found associations between age, gender, NS scores as 
well as RD scores in general population (41). 
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The possible functional mechanism underlying the results may be differences in expression in brain of the 
genes studied.  T-carriers of BDNF rs6188880 have been found to have lower expression of BDNF in frontal 
cortex and higher expression in cerebellum, and there is an increasing trend for the T-allele expression in 
putamen. No difference has been found in the expression of NRG1 rs3924999 between different brain 
regions (42).  The interplay between 5-HTTLPR and BDNF has been found to contribute for the risk of major 
depressive disorder especially in presence of stressful life events (43). We have earlier showed the SERT ss-
allele to associate with higher Persistence (P) scores in depression (44). However, in the present study our 
primary aim was to explore the possible interactions between BDNF and NRG1.  
 
All patients included had an MDD episode of at least moderate severity. The dosage and adherence to 
antidepressant medication were monitored during the follow-up period. The ethnic background of the 
sample was homogenous. We chose the observation period of six weeks in order to better detect a 
possible change in temperament profile as in general acute phase SSRI medication trials should last at least 
four to six weeks (45). Due to the small sample size there is a risk of both type 1 and type 2 errors. The 
current results should be considered as preliminary, and need to be replicated in other samples.  
 
According to the present results, both BDNF and NRG1 are associated with temperament traits during 
depression and may influence recovery from clinical depression.  
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Table 1. The genotype distributions of both BDNF and NRG1 SNPs according to temperament dimensions and MADRS scores at baseline and endpoint.  
 
         
All patients  
(n=98 baseline, n=88 
endpoint) 
BDNF rs11030101 (n=97 
baseline, n=87 endpoint) 
BDNF rs61888800 (n=98 
baseline, n=88 endpoint) 
NRG1 rs3924999 (n=98 
baseline, n=88 endpoint) 
NRG1 rs6994992 (n=98 
baseline, n=88 endpoint) 
Temperament dimension  
(mean + SD) 
 TT 
(n=23) 
TA 
(n=46) 
AA  
(n=57) 
GG 
(n=3) 
GT 
(n=23) 
TT 
(n=7) 
GG 
(n=40) 
GA 
(n=47) 
AA  
(n=11) 
CC 
(n=32) 
CT 
(n=53) 
TT  
(n=13) 
 
Novelty seeking baseline 
 
19.6 
±7.5 
 
19.5 
±6.9 
 
20.8 
±7.6 
 
17.4 
±7.7 
 
19.9 
±7.1 
 
19.7 
±7.4 
 
16.0 
±10.6 
 
18.3 
±7.4 
 
19.4 
±6.7 
 
25.0 
±9.2 
 
20.2 
±6.7 
 
18.8 
±7.5 
 
21.4 
±9.4 
 
Novelty seeking endpoint 
 
20.9 
±7.4 
 
20.9 
±6.8 
 
21.5 
±7.7 
 
20.0 
±7.7 
 
20.4 
±6.9 
 
21.9 
±7.6 
 
19.2 
±10.7 
 
20.0 
±7.0 
 
20.6 
±7.2 
 
25.2 
±8.8 
 
20.5 
±6.9 
 
20.4 
±7.3 
 
23.4 
±8.8 
 
Harm avoidance baseline 
 
23.6 
±7.0 
 
23.1 
±6.8 
 
23.8 
±7.9 
 
24.0 
±5.5 
 
24.1 
±6.4 
 
22.5 
±7.6 
 
25.7 
±8.3 
 
25.6 
±6.3 
 
22.1 
±7.2 
 
23.2 
±6.6 
 
24.2 
±6.8 
 
24.1 
±6.9 
 
20.3 
±6.9 
 
Harm avoidance endpoint 
 
21.8 
±8.0 
 
21.6 
±7.2 
 
22.7 
±8.9 
 
20.6 
±7.0 
 
23.1 
±6.6 
 
20.0 
±9.8 
 
21.3 
±7.4 
 
22,6 
±8,3 
 
20.7 
±7.9 
 
23.2 
±6.4 
 
22.4 
±8.4 
 
22.5 
±7.9 
 
17.8 
±6.2 
 
Reward dependency baseline 
 
15.5 
±4.0 
 
15.6 
±4.6 
 
15.6 
±3.8 
 
15.4 
±3.7 
 
15.8 
±3.9 
 
15.4 
±4.1 
 
14.1 
±3.1 
 
14,7 
±4,1 
 
15.9 
±3.8 
 
17.2 
±3.0 
 
16.0 
±3.8 
 
15.5 
±4.2 
 
14.8 
±3.2 
 
Reward dependency endpoint 
 
16.0 
±3.7 
 
 
15.6 
±4.0 
 
16.1 
±3.9 
 
15.9 
±3.3 
 
16.1 
±3.8 
 
15.7 
±3.8 
 
16.2 
±3.3 
 
15,8 
±3,3 
 
15.7 
±4.0 
 
17.4 
±4.3 
 
16.0 
±3.7 
 
16.3 
±3.9 
 
14.5 
±2.6 
Persistence baseline 4.4 
±2.1 
3.6 
±1.7 
4.4 
±2.1 
5.0 
±2.1 
4.3 
±2.2 
4.4 
±1.9 
5.4 
±1.4 
4,2 
±2,1 
4.6 
±2.0 
4.3 
±2.1 
4.6 
±1.9 
4.2 
±2.2 
4.9 
±1.8 
Persistence endpoint 4.4 
±2.1 
4.2 
±1.8 
4.0 
±2.2 
5.0 
±2.0 
4.3 
±2.0 
4.2 
±2.1 
6.0 
±1.4 
4,1 
±2,2 
4.6 
±2.0 
4.3 
±1.9 
4.8 
±2.1 
4.1 
±2.0 
4.7 
±2.1 
 
MADRS baseline score  
(mean + SD) 
 
27.0 
±5.6 
 
28.4 
±5.2 
 
26.0 
±5.7 
 
28.0 
±6.0 
 
26.7 
±5.3 
 
27.8 
±5.7 
 
27.9 
±9.0 
 
28,6 
±5,4 
 
26.1 
±5.9 
 
26.6 
±5.6 
 
27.3 
±6.4 
 
26.9 
±5.7 
 
27.9 
±4.3 
 
MADRS endpoint score  
(mean + SD) 
 
12.2 
±8.2 
 
12.4 
±8.2 
 
12.6 
±8.4 
 
11.3 
±8.3 
 
12.3 
±7.9 
 
11.9 
±8.5 
 
12.3 
±10.3 
 
12,1 
±8,5 
 
12.4 
±8.7 
 
11.3 
±5.0 
 
11.7 
±8.8 
 
12.1 
±7.8 
 
13.1 
±8.7 
Table 2. Results of the two ANCOVA models, in which temperament dimension changes 
(endpoint-baseline) of NS and RD were used as target variables and BDNFrs61888800 and 
NRG1rs6994992 or NRG rs3924999 genotypes as factors and MADRS score change and age as 
covariates.  
 
 Novelty seeking change Reward dependency change 
 ηp2 p power ηp2 p power 
Complete model 0.151* 0.019 0.82 0.169 0.009 0.876 
       
Explaining variable       
BDNF rs61888800  
GG/T-carriers 
0.057 0.029     
NRG1 rs6994992  
CC/T-carriers 
NRG1 rs3924999 
GG/A-carriers 
0.036 0.088   
 
0.076 
 
 
0.012 
 
MADRS change 
Gender 
0.052 0.039  0.025 
0.013 
0.153 
0.302 
 
Age 0.008 0.428  0.030 0.117  
  * Model 2: Including both BDNFrs61888800 GG/T-carriers and NRG1 rs6994992 CC/T-carriers 
 
